CN106974932B - 阴道炎的治疗 - Google Patents
阴道炎的治疗 Download PDFInfo
- Publication number
- CN106974932B CN106974932B CN201610997927.6A CN201610997927A CN106974932B CN 106974932 B CN106974932 B CN 106974932B CN 201610997927 A CN201610997927 A CN 201610997927A CN 106974932 B CN106974932 B CN 106974932B
- Authority
- CN
- China
- Prior art keywords
- vaginal
- cultures
- zeolite
- clinoptilolite
- healthy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 206010046914 Vaginal infection Diseases 0.000 title abstract description 8
- 201000008100 Vaginitis Diseases 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 57
- 239000000126 substance Substances 0.000 claims abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 23
- 244000005700 microbiome Species 0.000 claims abstract description 21
- 241000736262 Microbiota Species 0.000 claims abstract description 14
- JYIBXUUINYLWLR-UHFFFAOYSA-N aluminum;calcium;potassium;silicon;sodium;trihydrate Chemical compound O.O.O.[Na].[Al].[Si].[K].[Ca] JYIBXUUINYLWLR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910001603 clinoptilolite Inorganic materials 0.000 claims abstract description 14
- 239000000003 vaginal tablet Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 235000015097 nutrients Nutrition 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 4
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 239000006071 cream Substances 0.000 claims abstract description 4
- -1 etc.) Substances 0.000 claims abstract description 4
- 239000000499 gel Substances 0.000 claims abstract description 4
- 239000008101 lactose Substances 0.000 claims abstract description 4
- 208000013464 vaginal disease Diseases 0.000 claims abstract description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 3
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 239000000443 aerosol Substances 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 229960005309 estradiol Drugs 0.000 claims abstract description 3
- 229930182833 estradiol Natural products 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims abstract description 3
- 239000006260 foam Substances 0.000 claims abstract description 3
- 239000002674 ointment Substances 0.000 claims abstract description 3
- 150000007524 organic acids Chemical class 0.000 claims abstract description 3
- 239000000829 suppository Substances 0.000 claims abstract description 3
- 239000000725 suspension Substances 0.000 claims abstract description 3
- 241000222122 Candida albicans Species 0.000 claims description 13
- 229940095731 candida albicans Drugs 0.000 claims description 13
- 241000222173 Candida parapsilosis Species 0.000 claims description 8
- 229940055022 candida parapsilosis Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 abstract description 10
- 208000037009 Vaginitis bacterial Diseases 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 208000031888 Mycoses Diseases 0.000 abstract description 4
- 235000005985 organic acids Nutrition 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 abstract 1
- 239000010457 zeolite Substances 0.000 description 94
- 229910021536 Zeolite Inorganic materials 0.000 description 93
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 93
- 238000002474 experimental method Methods 0.000 description 45
- 230000012010 growth Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 238000003556 assay Methods 0.000 description 24
- 241000207201 Gardnerella vaginalis Species 0.000 description 23
- 238000011534 incubation Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 230000002503 metabolic effect Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 14
- 241000218492 Lactobacillus crispatus Species 0.000 description 14
- 239000008272 agar Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 11
- 241001561398 Lactobacillus jensenii Species 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000003026 viability measurement method Methods 0.000 description 8
- 241000222126 [Candida] glabrata Species 0.000 description 7
- GJJYZOBRHIMORS-GQOAHPRESA-K aloglutamol Chemical compound OCC(N)(CO)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Al](O)O GJJYZOBRHIMORS-GQOAHPRESA-K 0.000 description 7
- 208000032343 candida glabrata infection Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 231100000747 viability assay Toxicity 0.000 description 7
- 244000199866 Lactobacillus casei Species 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 description 5
- 206010014599 encephalitis Diseases 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 229940017800 lactobacillus casei Drugs 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 229960004884 fluconazole Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000522 vaginal cream Substances 0.000 description 3
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 2
- 241000193818 Atopobium Species 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241000207202 Gardnerella Species 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 206010023927 Lassa fever Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960004375 ciclopirox olamine Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 229940087419 nonoxynol-9 Drugs 0.000 description 2
- 229920004918 nonoxynol-9 Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
- 229940044959 vaginal cream Drugs 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000973040 Macrococcus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000604449 Megasphaera Species 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000255129 Phlebotominae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 244000000072 vaginal pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194288.5 | 2015-11-12 | ||
| EP15194288.5A EP3167890A1 (de) | 2015-11-12 | 2015-11-12 | Behandlung von vaginitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106974932A CN106974932A (zh) | 2017-07-25 |
| CN106974932B true CN106974932B (zh) | 2021-05-04 |
Family
ID=54542054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610997927.6A Active CN106974932B (zh) | 2015-11-12 | 2016-11-11 | 阴道炎的治疗 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170136060A1 (https=) |
| EP (2) | EP3167890A1 (https=) |
| JP (1) | JP6792420B2 (https=) |
| KR (1) | KR102335607B1 (https=) |
| CN (1) | CN106974932B (https=) |
| AU (1) | AU2016247097B2 (https=) |
| CA (1) | CA2947570C (https=) |
| ES (1) | ES2719223T3 (https=) |
| TR (1) | TR201904382T4 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3524055A1 (de) * | 2018-02-08 | 2019-08-14 | BCSK Biocid GmbH | Antibakterielles und spermizides gleitmittel |
| US20230407365A1 (en) * | 2022-06-21 | 2023-12-21 | Pamela Miles | Diagnostic tool for screening the impact of product ingredients for urogenital microbiomes therapies |
| CN116059177A (zh) * | 2022-12-14 | 2023-05-05 | 迪沙药业集团有限公司 | 一种克林霉素磷酸酯组合物及其制备方法 |
| CN117535208B (zh) * | 2024-01-04 | 2024-03-29 | 四川厌氧生物科技有限责任公司 | 一种卷曲乳杆菌及其在女性生殖道健康中的应用 |
| JP7813333B1 (ja) * | 2024-11-08 | 2026-02-12 | 日本食品化工株式会社 | 膣常在菌叢バランス改善剤及び膣用組成物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000064586A1 (de) * | 1999-04-26 | 2000-11-02 | Tihomir Lelas | Vorrichtung zum mikronisieren von materialien |
| CN1301142A (zh) * | 1998-04-20 | 2001-06-27 | 普莱特克斯产品公司 | 有吸臭能力的纤维制品及其制备方法 |
| WO2006132515A1 (en) * | 2005-06-09 | 2006-12-14 | Inha-Industry Partnership Institute | Agent for the treatment of vaginitis containing mandelic acid as an active ingredient |
| WO2007054085A2 (de) * | 2005-11-11 | 2007-05-18 | Ljubicic, Mijo | Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum |
| WO2009133413A1 (en) * | 2008-04-28 | 2009-11-05 | Novatech D.O.O. | Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165139T3 (es) * | 1998-04-30 | 2002-03-01 | Vesely Renata Maria Cavaliere | Composiciones farmaceuticas que contienen lactobacillus brevis y lactobacillus salivarius para el tratamiento de infecciones vaginales. |
| SI2040837T1 (sl) | 2006-07-04 | 2012-10-30 | Gaston Glock | Postopek za odločenje težkih kovin |
| CN101594888A (zh) * | 2006-12-15 | 2009-12-02 | 欧兰益生公司 | 含有产乳酸细菌的吸收制品 |
| EP2358642B2 (de) * | 2008-11-21 | 2022-12-07 | Froximun AG | Klinoptilolith oder klinoptilolithhaltige gemische |
| KR101198572B1 (ko) * | 2010-07-09 | 2012-11-06 | 경희대학교 산학협력단 | 미생물 감염증 치료 또는 개선용 조성물 |
-
2015
- 2015-11-12 EP EP15194288.5A patent/EP3167890A1/de not_active Withdrawn
-
2016
- 2016-10-19 AU AU2016247097A patent/AU2016247097B2/en not_active Ceased
- 2016-10-25 EP EP16455004.8A patent/EP3167891B1/de active Active
- 2016-10-25 ES ES16455004T patent/ES2719223T3/es active Active
- 2016-10-25 TR TR2019/04382T patent/TR201904382T4/tr unknown
- 2016-11-03 CA CA2947570A patent/CA2947570C/en active Active
- 2016-11-11 CN CN201610997927.6A patent/CN106974932B/zh active Active
- 2016-11-11 US US15/349,727 patent/US20170136060A1/en not_active Abandoned
- 2016-11-11 JP JP2016220187A patent/JP6792420B2/ja not_active Expired - Fee Related
- 2016-11-14 KR KR1020160151167A patent/KR102335607B1/ko not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301142A (zh) * | 1998-04-20 | 2001-06-27 | 普莱特克斯产品公司 | 有吸臭能力的纤维制品及其制备方法 |
| WO2000064586A1 (de) * | 1999-04-26 | 2000-11-02 | Tihomir Lelas | Vorrichtung zum mikronisieren von materialien |
| WO2006132515A1 (en) * | 2005-06-09 | 2006-12-14 | Inha-Industry Partnership Institute | Agent for the treatment of vaginitis containing mandelic acid as an active ingredient |
| WO2007054085A2 (de) * | 2005-11-11 | 2007-05-18 | Ljubicic, Mijo | Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum |
| WO2009133413A1 (en) * | 2008-04-28 | 2009-11-05 | Novatech D.O.O. | Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3167891A1 (de) | 2017-05-17 |
| CN106974932A (zh) | 2017-07-25 |
| EP3167890A1 (de) | 2017-05-17 |
| TR201904382T4 (tr) | 2019-04-22 |
| BR102016026252A2 (pt) | 2017-05-23 |
| JP2017088603A (ja) | 2017-05-25 |
| CA2947570C (en) | 2021-08-10 |
| ES2719223T3 (es) | 2019-07-09 |
| US20170136060A1 (en) | 2017-05-18 |
| JP6792420B2 (ja) | 2020-11-25 |
| AU2016247097B2 (en) | 2021-12-02 |
| KR102335607B1 (ko) | 2021-12-06 |
| EP3167891B1 (de) | 2019-01-23 |
| KR20170055932A (ko) | 2017-05-22 |
| AU2016247097A1 (en) | 2017-06-01 |
| CA2947570A1 (en) | 2017-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106974932B (zh) | 阴道炎的治疗 | |
| US10946049B2 (en) | Use of gram negative species to treat atopic dermatitis | |
| US20210169943A1 (en) | Use of gram negative species to treat atopic dermatitis | |
| US10653727B2 (en) | Use of gram negative species to treat atopic dermatitis | |
| BR102016026252B1 (pt) | Uso de clinoptilolita no tratamento de vaginite | |
| HK40047985A (en) | Use of gram negative species to treat atopic dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |